SCHEMBL2464798

SCHEMBL2464798

COC(C)OC.COCCOCCOC

nearest known ligand 0.35

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
CA2 P00918 1/20 0.35
PIK3CD O00329 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Isopropyl Alcohol SCHEMBL6142875 0.92 MEN1 (0.34) CA2
SCHEMBL1076991 0.91 PIK3CD (0.36) PIK3CD
SCHEMBL892398 0.87 CA2 (0.32) CA2
SCHEMBL15503611 0.85 LMNA (0.32) CA2
SCHEMBL23647292 0.80 CA2 (0.44) CA2
SCHEMBL5668460 0.80 CA2 (0.44) CA2
SCHEMBL11219700 0.80 CA2 (0.44) CA2
SCHEMBL125676 0.80 CA2 (0.44) CA2
SCHEMBL10835191 0.80 CA2 (0.44) CA2
SCHEMBL16546847 0.80 CA2 (0.44) CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9353038-B2 Methods for preparing fluorinated vinyl ethers BAXTER INTERNATIONAL, INC. (US) 2016-05-31 US disclosed
EP-2370419-A1 MALTOL ETHER PROCESSES AND INTERMEDIATES Shionogi&Co., Ltd. (JP) 2011-10-05 EP disclosed
US-20100267995-A1 METHODS FOR PREPARING FLUORINATED VINYL ETHERS BAXTER INTERNATIONAL INC. (US) 2010-10-21 US disclosed
WO-2010067176-A1 MALTOL ETHER PROCESSES AND INTERMEDIATES SHIONOGI & CO., LTD. (JP) 2010-06-17 WO disclosed
US-7687635-B2 Metal complexes useful in metathesis and other reactions TELENE S.A.S. (FR) 2010-03-30 US disclosed
EP-1743899-B1 Metal complexes for use in metathesis, atom transfer radical reactions, addition polymerisation and vinylation reactions, methods and intermediates for making them TELENE SAS (FR) 2009-04-22 EP disclosed
EP-1206937-B1 NITROIMIDAZOLE EXTERNAL PREPARATIONS FOR THE TREATMENT OF ATOPIC DERMATITIS SHOEI CO LTD (JP) 2008-01-23 EP disclosed
US-20070185343-A1 Metal complexes for use in olefin metathesis and atom group transfer reactions UNIVERSITEIT GENT (BE) 2007-08-09 US disclosed
EP-1414867-B1 POLYMERS AND THEIR SYNTHESIS UNILEVER PLC (GB) 2007-03-14 EP disclosed
EP-1743899-A1 Metal complexes for use in metathesis, atom transfer radical reactions, addition polymerisation and vinylation reactions, methods and intermediates for making them Universiteit Gent (BE) 2007-01-17 EP disclosed
US-6448247-B1 TACHYKININ RECEPTOR ANTAGONIST; ESPECIALLY TO THE RECEPTORS FOR SUBSTANCE P (WHICH RECEPTORS ARE GENERALLY REFERRED TO AS ?NEUROKININ 1 RECEPTORS?) SANKYO COMPANY, LIMITED (JP) 2002-09-10 US disclosed
EP-1206937-A1 NITROIMIDAZOLE EXTERNAL PREPARATIONS FOR DERMATOSIS SHOEI CO., LTD. (JP) 2002-05-22 EP disclosed
EP-0776893-B1 Azaheterocyclic compounds having tachykinin receptor antagonist activity; Nk1 and NK2 SANKYO CO (JP) 2002-02-27 EP disclosed
US-6159967-A Heterocyclic compounds having tachykinin receptor antagonist activity their preparation and their use SANKYO COMPANY, LIMITED (JP) 2000-12-12 US disclosed
US-5763548-A ADDITION POLYMERIZATION USING TRANSITION METAL CATALYSTS CARNEGIE-MELLON UNIVERSITY (US) 1998-06-09 US disclosed
EP-0776893-A1 Azaheterocyclic compounds having tachykinin receptor antagonist activity; Nk1 and NK2 SANKYO COMPANY LIMITED (JP) 1997-06-04 EP disclosed
EP-0183848-A1 POLYAZAHETEROCYCLIC DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITION Yoshitomi Pharmaceutical Industries, Ltd. (JP) 1986-06-11 EP disclosed
EP-0024965-B1 FLUORINATED METHYL BETA-ALANINE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM MERRELL TORAUDE ET COMPAGNIE (FR) 1983-04-27 EP disclosed
US-4375477-A ENZYME INHIBITORS MERRELL TORAUDE ET COMPAGNIE (FR) 1983-03-01 US disclosed
EP-0024965-A1 Fluorinated methyl beta-alanine derivatives, their preparation and pharmaceutical compositions containing them MERRELL TORAUDE ET COMPAGNIE (FR) 1981-03-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185343-A1 Metal complexes for use in olefin metathesis and atom group transfer reactions ME1, ME3, COASY CA2 763/4885PIK3CD 4179/4885
US-20100267995-A1 METHODS FOR PREPARING FLUORINATED VINYL ETHERS VAV1, CYP4F2, CYP2F1 CA2 691/4885PIK3CD 1627/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.